("Omnicell," "we," "our," "us," "management," or the "Company"), a leader in transforming the pharmacy and nursing care delivery model, today announced updates to its second quarter and full year 2025 ...

Format: Presentation and one-on-one investor meetings Presentation Time: 4:55 p.m. ET Corbus Pharmaceuticals Holdings, Inc.

The Securities and Exchange Commission (SEC) has been recognized as global leader in good governance for the fifth straight ...

The Securities and Exchange Commission (SEC) said Wednesday it revoked the corporate registration and financing license of ...

A financial professional and three colleagues explain the fluctuations in the 10-year Treasury bond and what investors should ...

The BC Securities Commission says a Vancouver cryptocurrency firm has been temporarily banned from trading securities and ...

The Securities and Exchange Commission (SEC) and BDO Foundation launch a partnership project to identify red flags of ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Q1 2025 Earnings Call Transcript May 13, 2025 Intellicheck, Inc. beats earnings expectations. Reported EPS is $-0.02, ...

As of March 31, 2025, the Company’s cash, cash equivalents and investments was $314.2 million. The Company expects that its cash, cash equivalents and investments, as of March 31, 2025, will fund its ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Company will host the second annual Contemporary Landscapes in Muscle Biology Research Symposium (CLIMB) on Friday, May 30 th, 2025 ...

First patient dosed in LINNET Phase 2 study of lorigerlimab in ovarian and other gynecologic cancers Clinical update on LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination ...